1. Introduction {#j_med-2016-0040_s_001}
===============

Malignant Fibrous Histiocytoma, MFH, is a primitive, often pleomorphic, soft tissue sarcoma characterized by fibrous tissue with fibroblasts, histiocytes and myofibro-blasts \[[@j_med-2016-0040_ref_001]-[@j_med-2016-0040_ref_005]\]. It was first described by O'Brein and Stout in 1964, as a 'fibrous histiocytoma or fibrous xanthoma.' It is assumed that in fibrous histiocytoma, cells behave as phagocytes but also form connective tissue fibers; whereas in pure histiocytoma no fibers are formed \[[@j_med-2016-0040_ref_005]\]. In 1983, Enzinger and Weiss, described storiform-pleomorphic, myxoid, giant cells, inflammatory and angiomatoid variants \[[@j_med-2016-0040_ref_006],[@j_med-2016-0040_ref_007]\].

Storiform-pleomorphic phenotype is the most frequent; few cases of low differentiation MFH can be distinguished in high-grade pleomorphic sarcoma, pleomorphic sarcoma with giant cells and inflammatory pleomorphic sarcoma \[[@j_med-2016-0040_ref_008]\].

MFH is the most common subtype of soft tissue sarcoma in adults, described in bone, viscera and skin \[[@j_med-2016-0040_ref_009]-[@j_med-2016-0040_ref_012]\], it remains a rare malignancy in the head and neck region (3-13% of all malignant lesions), and it occurs even more rarely in the larynx, 10-15% of these cases \[[@j_med-2016-0040_ref_013]-[@j_med-2016-0040_ref_015]\].

As all sarcomas, the development of MFH is unrelated to smoking and alcohol consumption. Some sarcomas are related to genetic syndromes such as Li Fraumeni, neuro-fibromatosis, or rarely Cutis Laxa \[[@j_med-2016-0040_ref_004],[@j_med-2016-0040_ref_016]\].

MFH can be correlated to hereditary mutations of oncosuppressor genes or environmental mutagens exposure as commonly reported in bowel tumors \[[@j_med-2016-0040_ref_017],[@j_med-2016-0040_ref_018]\]; it is one of the most common radiation-associated sarcomas, accounting for almost 50% of all cases occurring in both bone and soft tissue \[[@j_med-2016-0040_ref_019],[@j_med-2016-0040_ref_020]\].

43 cases of MFH of the larynx have been described in literature since 1972. Rolander et al. studied a review of case reports of MHF: 8 cases in supraglottic region (2 of these of epiglottis, 4 of aryepiglottic fold, 1 of Morgagni ventricle, 1 not specified); 19 glottis region (17 of vocal cords, 1 of anterior commissura, 1 not specified); 8 in subglottis region; 6 in not specified region; 1 in hemilarynx and 1 case of transglottic cancer (vocal cord and Morgagni ventricle) ([Table 1](#j_med-2016-0040_tab_001){ref-type="table"}).

###### 

Clinical case review of MFH of the larynx.

  Author                 Year   Ages/Sex   Location                            Treatment/Recurrence
  ---------------------- ------ ---------- ----------------------------------- --------------------------------------------------------------------
  Rolander et al         1972   56/M       Epiglottis                          Supraglottic laryngectomy, neck dissection/NER
  Coyas et al            1974   67/M       Vocal Cord                          Tumor excision/Recurrence
  Canalis et al          1975   53/M       Vocal Cord                          Piecemeal excision/Recurrence
  Ribari et al           1975   35/M       Subglottis                          Tumor excision/Radiotherapy
  Ferlito                1976   46/M       Larynx                              Total Laryngectomy + Radiotherapy/Recurrence
  Johnson and Poushtes   1977   67/F       Subglottis                          Tumor excision/Recurrence
  Ferlito                1978   58/M       Subglottis                          Tumor excision/Recurrence
  Ferlito                1979   68/M       Aryepiglottic fold                  Total Laryngectomy /NER
  Keenan et al           1979   22/F       Subglottis                          Tumor endoscopic excision/Recurrence
  Setzen et al           1979   ND         ND                                  ND
  Setzen et al           1979   ND         ND                                  ND
  Ogura et al            1980   22/F       Subglottis                          Segmental cricotracheal resection/NER
  Ogura et al            1980   28/M       Subglottis                          Partial cricotracheal resection/NER
  Neblett and Coller     1891   22/F       Morgagni Ventricle                  Partial Laryngectomy/NER
  Bremer et al           1982   45/M       ND                                  ND
  Bremer et al           1982   30/M       ND                                  ND
  Yokoi et al            1982   64/F       Vocal cord                          Tumor excision /NER
  Ferlito et al          1983   67/M       Vocal cord                          Total Laryngectomy + Radiotherapy/ Recurrence
  Ferlito et al          1983   51/M       Vocal cord                          Total Laryngectomy /NER
  Ferlito et al          1983   63/M       Emilarynx                           Laryngectomy and pharyngo esophagectomy /NER
  Ferlito et al          1983   8/F        Subglottis                          ND
  Radamass               1984   45/M       Vocal Cord                          Total Laryngectomy/NER
  Lobe and Katewkamp     1984   67/M       ND                                  Radiotherapy/NER
  Volmer                 1985   70/M       Vocal Cord                          Tumor excision + Radiotherapy / NER
  Volmer                 1985   38/M       Vocal Cord                          Tumor excision / NER
  Godoy et al            1986   26/F       Subglottis                          Total Laryngectomy /NER
  Barnes e Kanbour       1988   68/M       Vocal cord                          Total Laryngectomy /NER
  Masuda et al           1989   80/M       Vocal cord                          Tumor excision / NER
  Saha et al             1989   58/M       Epiglottide                         Tracheotomy and Radiotherapy/ Recurrence
  Majumder et al         1989   45/M       Aryepiglottic fold Supraglottis     Total Laryngectomy + Radiotherapy/NER
  Jordan and Soames      1989   54/M       Vocal cord                          Tumor excision / Recurrence
  Colev et al            1989   57/M       Aryepiglottic fold                  ND
  Colev et al            1989   64/M       Vocal cord                          ND
  Colev et al            1989   75/M       Vocal cord                          ND
  Rosa et al             1990   78/M       Vocal cord                          Chordectomy/ Recurrence
  Bernaldez et al        1991   54/M       Vocal cord and Morgagni ventricle   Total Laryngectomy /NER
  Weber et al            1992   ND/M       Vocal cord                          ND
  Weber et al            1992   ND/M       Plica ariepiglottica                ND
  Harmoir et al          1993   24/F       ND                                  ND
  Kuwabara et al         1993   46/M       Vocal cord                          CO2 laser Tumor excision /NER
  Pastore et al          2001   32/M       Laryngeal Vestibule                 Lateral Pharyngothiroidotomy, thyroid-hyoidpessia+radiotherapy/NER
  Ortizbish et al        2004   54/M       Vocal cord                          Chordectomy with laryngofissure/ Recurrence
  Ortizbish et al        2004   67/M       Anterior Commissura                 Tumor excision /NER
  Anghelina et al        2009   59/M       Vocal cord                          Tumor excision /NER
  Testa et al            2015   84/M       Cord-commissural                    CO2 laser Tumor excision /NER

Surgery with en-block resection of tumor is the first treatment choice: 60% of patients may survive over 5 years, and 40% over 10 years \[[@j_med-2016-0040_ref_014],[@j_med-2016-0040_ref_015],[@j_med-2016-0040_ref_019]\]. Radiotherapy is given to patients with risk of recurrence, in non-surgical patients or in cases with metastasis \[[@j_med-2016-0040_ref_020]-[@j_med-2016-0040_ref_024]\].

Adjuvant or neoadjuvant chemotherapy is suggested when patients have high risk of recurrence \[[@j_med-2016-0040_ref_025]-[@j_med-2016-0040_ref_027]\]. The prognosis is related to tumor differentiation, vascular invasion, size (over 5 cm), metastasis \[[@j_med-2016-0040_ref_025]-[@j_med-2016-0040_ref_028]\].

Endothelial Progenitor Cells (EPCs) a promising target of cell based therapy, just used in several benign and malignant diseases, should be a possible innovative non surgical approach \[[@j_med-2016-0040_ref_029]-[@j_med-2016-0040_ref_037]\].

We present one case of a cord-commissural MFH of larynx, the first treated in microlaryncoscopy with CO^2^ laser.

2. Case report {#j_med-2016-0040_s_002}
==============

C.L., 84 year-old male, smoker for 50 years, was admitted to the Department of Otorhinolaryngology of the Second University of Naples in March 2009. He had had hoarseness for 8 months and there had been familial cases of tumors, such as lung adenocarcinoma. During fiberoptic laryngoscopy, we discovered a red-violaceous nodular lesion of the left vocal cord and of the anterior commissure, with hypomobility of the left vocal chord ([Figure 1](#j_med-2016-0040_fig_001){ref-type="fig"}); there was no palpable cervical lymphadenopathy. CT-scan of the neck and thorax was performed, showing a laryn-geal mass infiltrating the left vocal cord and the anterior commissural; no cervical lymph nodes and no metastases were found. Transoral endoscopic cordectomy of the left vocal cord and of anterior commissural was performed in microlaryngoscopy with CO~2~ (IVd) ([Figure 2](#j_med-2016-0040_fig_002){ref-type="fig"}).

![Fibrolaryngoscopy: red-violaceous nodular lesion of the left vocal cord and anterior commissure.](j_med-2016-0040_fig_001){#j_med-2016-0040_fig_001}

![Microlaryngoscopic vision of the operative field after laser cordectomy.](j_med-2016-0040_fig_002){#j_med-2016-0040_fig_002}

The surgical specimen was sent for histological examination.

At microscopic evaluation, a lesion, was observed, mostly formed of spindle-shaped malignant cells arranged in a fascicular/storiform pattern of growth, with several highly pleomorphic elements, in the corion. Moreover, a significant number of osteoclast-like giant-cells, with hypercrhomatic and slightly atypical nuclei, were found. A focal collagen deposition, consisting of bundles of fibrillar eosinophilic material, was associated.

At the immunohistochemical exam, the lesion showed a strong and diffuse positivity to vimentin and mild reactivity for CD68, more prominently in the giant cells counterpart. Finally, a diagnosis of malignant fibrous histiocytoma (MFH) was made ([Figure 3](#j_med-2016-0040_fig_003){ref-type="fig"}).

![Microscopic evaluation showed a lesion mostly formed of spindle-shaped malignant cells arranged in a fascicular/stori-form pattern of growth, with several highly pleomorphic elements, was observed in the corion. (green arrow). Moreover, a significant number of osteoclast-like giant-cells, with hyperchromatic and slightly atypical nuclei, were found (blue arrows). A focal collagen deposition, consisting of bundles of fibrillar eosinophilic material, was associated (red arrows). At the immunohistochemical exam, the lesion showed a strong and diffuse positivity to vimentin and a mild reactivity to CD68, more prominently in the giant cells counterpart. Finally, a diagnosis of malignant fibrous histiocytoma (MFH) was made.](j_med-2016-0040_fig_003){#j_med-2016-0040_fig_003}

At follow-up, laryngoscopy was performed every month for the first year after surgery and then every two months during the last three years. At the last follow-up examination, five year after surgery, the patient was asymptomatic and there was no recurrence of lesions.

**Ethical approval**: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors' institutional review board or equivalent committee.

**Informed consent**: Informed consent has been obtained from all individuals included in this study.

3. Discussion {#j_med-2016-0040_s_003}
=============

In 1964, O' Brein and Stout first defined MHF, in order to describe a histiocytic-like tumor with predominant fibroblasts \[[@j_med-2016-0040_ref_005]\]. MFH of the larynx is a rare disease, comprising approximately less than 2% of all head and neck tumors \[[@j_med-2016-0040_ref_019]\]. It is divided histologically into five variants: storiform-pleomorphic, myxoid, giant cells, inflammatory and angiomatous. Immunohistochemistry is needed to differentiate MFH from other malignant tumors such as sarcomatoid carcinoma (AE1/AE3-negativity), malignant shwannoma and melanoma (S100-negativity), angiosarcoma (CD3- negativity), rhabdomyosarcoma (myoglobin-negativity) \[[@j_med-2016-0040_ref_007]\].

The neoplastic cells of MFH are positive to vimentin and CD68 (histiocytic marker) and focally positive to S100 (neuroectodermic marker) and to smooth muscle actin (SMA) \[[@j_med-2016-0040_ref_007]\]. Age related incidence ranges from 4 to 84 (our patient) years; only one case occurring in a child (8 year-old female, 2,3% of all cases) \[[@j_med-2016-0040_ref_009]\], 8 cases (4 female and 4 male, 18,2% of all cases) \[[@j_med-2016-0040_ref_009]\] all between 20-30 years old. MFH is more common in male patients than in female (M:F, 4:1) \[[@j_med-2016-0040_ref_020]\]. Radiotherapy is given when patients have high risk of recurrence, in non-operated patients or in cases with metastasis; adjuvant or neoadjuvant chemotherapy is suggested when patients have high risk of recurrence \[[@j_med-2016-0040_ref_020]-[@j_med-2016-0040_ref_024]\]. The prognosis is related to tumor differentiation, vascular invasion, size (over 5 cm), resection margins, metastasis: 60% of the patients may survive over 5 years, and 40% of the patients may survive over 10 years \[[@j_med-2016-0040_ref_025]-[@j_med-2016-0040_ref_027]\].

Of the 43 cases of MFH of the larynx described since 1972 (Rolander et al.: 8 cases occurred in the supraglottic region (2 of these of epiglottis, 4 of aryepiglottic fold, 1 of Morgagni ventricle, 1 not specified); 19 in glottis region (17 of vocal cords, 1 of anterior commissura, 1 not specified); 8 in the subglottis region; 6 in unspecified regions; 1 in hemilarynx and 1 case of transglottic cancer (vocal cord and Morgagni ventricle) ([Table 1](#j_med-2016-0040_tab_001){ref-type="table"}). We have indicated treatments, recurrences and follow-ups in tab.1 \[[@j_med-2016-0040_ref_020]\]. Surgical intervention is the first choice of treatment and the majority of authors used demolitive surgical techniques: total, partial or supraglottic laryngectomy; traditional cordectomy, tumor excision, partial cricotracheal resection; in 1994 Kuwabara et al., described a glottic MFH (vocal cord) treated with CO^2^ laser \[[@j_med-2016-0040_ref_022]\]. In our case CO^2^ laser treatment wasn't associated to vocal cord lesion or paralysis \[[@j_med-2016-0040_ref_038]\].

In literature 8 Italian cases of MFH occurring in Italy were described from 1976 (Ferlito et al.) \[[@j_med-2016-0040_ref_023]\] to 2001 (Pastore et al.) \[[@j_med-2016-0040_ref_024]\], 7 male and 1 female, mean age 49.7 : 2 glottic cases, 2 supraglottic, 2 ipoglottic, 1 transglottic and 1 undetermined ([Table 2](#j_med-2016-0040_tab_002){ref-type="table"}) \[[@j_med-2016-0040_ref_020]-[@j_med-2016-0040_ref_022]\].

###### 

Italian cases of MFH of the larynx.

  Author          Year   Ages/Sex   Location              Treatment/Recurrence                                                 Subsequent Tratment
  --------------- ------ ---------- --------------------- -------------------------------------------------------------------- ---------------------------------------------
  Ferlito         1976   46/M       NS                    Total Laryngectomy/NER                                               Hypopharyngectomy+CT
  Ferlito         1978   58/M       Hypoglottis           Tumor excision/Recurrence                                            Emilaringectomia e poi Laringectomia Totale
  Ferlito         1979   68/M       Aryepiglottic fold    Total Laryngectomy/NER                                               
  Ferlito et al   1983   67/M       Vocal Cord            Total Laryngectomy + RT/Ricurrence                                   ND
  Ferlito et al   1983   51/M       Vocal Cord            Total Laryngectomy/NER                                               
  Ferlito et al   1983   63/M       Emilarynx             Laryngectomy and pharyngo esophagectomy /NER                         \-
  Ferlito et al   1983   8/F        Subglottis            ND                                                                   ND
  Pastore et al   2001   32/M       Laryngeal Vestibule   Lateral Pharyngothiroidotomy, thyroid-hyoidpessia+radiotherapy/NER   \-
  Testa et al     2014   84/M       Cord-commissural      CO2 Laser/NER                                                        

4. Conclusions {#j_med-2016-0040_s_004}
==============

Our case represents the second case in literature of commissural MFH. Ortiz Bish et al. in 2004 described the first in 2004 \[[@j_med-2016-0040_ref_039]\], a 64 year old male who underwent traditional tumor excision and 6 months after surgery he did not present any recurrences \[[@j_med-2016-0040_ref_025]-[@j_med-2016-0040_ref_027]\]. We performed CO^2^~-~laser tumor excision, the first time used in Italy for MFH of larynx.

Five years after surgery, without any adjuvant treatment, did not present any recurrence.

Malignant fibrous histiocytomas are a very rare mesenchymal neoplasm of the larynx. At present, no guidelines for laryngeal MFH exist because of lack of evidence-based data, the treatment of choice is surgical, in some cases associated with radiotherapy and chemotherapy. An innovative approach should be considered a cell based therapy using Endothelial Progenitor Cells (EPCs) \[[@j_med-2016-0040_ref_029]-[@j_med-2016-0040_ref_037]\]. EPCs pathogenic mechanisms involving in vascular and non vascular diseases includes several biomarkers and Ca^2+^ toolkit. \[[@j_med-2016-0040_ref_040]-[@j_med-2016-0040_ref_049]\].

We found 43 cases of MFH of the larynx, in literature the presented case is the second cord-commissural case described and the only commissural one treated with CO^2^ laser surgery.
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